Skip to main content

Enovis Introduces DynaNail Helix™ – a New Twist on Hindfoot Fusions

Written by Customer Service on . Posted in Public Companies.

Designed with our patented and proven NiTiNOL technology, DynaNail Helix™ revolutionizes dynamic compression in foot & ankle fusion

DynaNail Helix Image

The new DynaNail Helix™ which is designed with Enovis' patented and proven NiTiNOL technology.
The new DynaNail Helix™ which is designed with Enovis’ patented and proven NiTiNOL technology.

Wilmington, DE, Nov. 17, 2022 (GLOBE NEWSWIRE) — Enovis Corporation (NYSE: ENOV), an innovation-driven medical technology company, announces the introduction of the DynaNail Helix™, the latest addition to the DynaNail® family and Enovis’ expansive suite of foot and ankle products. DynaNail Helix is designed to achieve sustained dynamic compression for subtalar fusion with an innovative, anatomically friendly design and simple, screw-like insertion.

Leveraging the same groundbreaking NiTiNOL compressive element technology from other DynaNail systems, the DynaNail Helix is smaller, easy to use, and comes with expanded indications.

“This is the same NiTiNOL technology used in the DynaNail intramedullary system. It provides sustained compression across the fusion site, which traditional screws cannot do,” said Dr. Christopher Hirosei, a foot and ankle orthopedic surgeon based in Boise, Idaho. “The Enovis DynaNail Helix NiTiNOL implants are as easy to use as traditional screws.” 

DynaNail Helix’s NiTiNOL compressive element comes pre-stretched and pre-loaded on a disposable nail guide for maximum efficiency. Like a screw, its threads allow for easy insertion. There are no transverse screws, eliminating the need for orthopedic surgeons to stretch the compressive element manually.

“The flexible, pseudo elastic NiTiNOL element that DynaNail Helix offers is unlike typical static fixation devices that are available on the market. Not only does DynaNail Helix offer intraoperative manual compression, but it also allows for up to 4mm of post-operative compression in response to bone resorption or settling,” said Gary Justak, President of Enovis Foot & Ankle. “This sustained compression is designed to give patients a better chance at healing faster, with fewer complications.”

The DynaNail Helix is one of several new products introduced by Enovis Foot & Ankle this year with active, adaptive healing technology designed to improve patient outcomes across the continuum of care.

For more information on the new DynaNail Helix, visit https://www.djoglobal.com/products/active-adaptive/dynanail-helix.

About Enovis
Enovis Corporation (NYSE: ENOV) is an innovation-driven, medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services, and integrated technologies fuels active lifestyles in orthopedics and beyond. For more information about Enovis, please visit www.enovis.com.

MK-10295

i Dr. Hirose is a paid consultant at Enovis.

Attachment

CONTACT: Media Contact:
Megan Foltz
Enovis
(609) 680-0996
Megan.Foltz@enovis.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.